Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Withdrawn 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Gliosarcoma 2Glioblastoma 2Central Nervous System Neoplasms 2Breast Neoplasms 2Uveal Melanoma 1Oligodendroglioma 1Neuroblastoma 1Neoplasm Metastasis 1Melanoma 1Lung Neoplasms 1Liver Neoplasms 1Glioma 1Carcinoma, Non-Small-Cell Lung 1Carcinoma, Hepatocellular 1Brain Neoplasms 1Astrocytoma 1

Interventions

Sorafenib 222lenvatinib 147Bevacizumab 131Nivolumab 87atezolizumab 81pembrolizumab 74Radiosurgery 71durvalumab 63sintilimab 61Oxaliplatin 60Fluorouracil 56Doxorubicin 47tislelizumab 46apatinib 45Radiofrequency Ablation 44Hepatectomy 43camrelizumab 41Leucovorin 41Radiotherapy 40tremelimumab 37Magnetic Resonance Spectroscopy 36regorafenib 34Capecitabine 30Immune Checkpoint Inhibitors 29Folfox protocol 29Cisplatin 28cabozantinib 26Gemcitabine 26Cyclophosphamide 26Ipilimumab 25

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Carcinoma, Hepatocellular × NSC 366140 × Clear all
NCT00003714 2012-02-22

Chemotherapy in Treating Patients With Unresectable Primary or Metastatic Kidney Cancer

M.D. Anderson Cancer Center

Phase 2 Withdrawn
Gastrointestinal

Carcinoma, Hepatocellular, Liver Neoplasms, Neoplasm Metastasis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡